Lipocine Inc. Files 8-K with Corporate Updates

Ticker: LPCN · Form: 8-K · Filed: 2025-06-04T00:00:00.000Z

Sentiment: neutral

Topics: corporate-governance, filing-update

Related Tickers: LPCN

TL;DR

LPCN filed an 8-K on June 4th covering corporate governance and shareholder votes.

AI Summary

Lipocine Inc. filed an 8-K on June 4, 2025, reporting on amendments to its articles of incorporation or bylaws, submission of matters to a vote of security holders, and financial statements and exhibits. The filing does not contain specific financial figures or details about the matters voted upon.

Why It Matters

This filing indicates routine corporate governance activities and potential changes to the company's structure or shareholder decisions, which are important for investors to monitor.

Risk Assessment

Risk Level: low — The filing is a routine 8-K reporting corporate actions and does not disclose significant new financial or operational risks.

Key Players & Entities

FAQ

What specific amendments were made to Lipocine Inc.'s articles of incorporation or bylaws?

The filing indicates that amendments were made, but the specific details of these amendments are not provided in the summary information.

What matters were submitted to a vote of Lipocine Inc.'s security holders?

The filing states that matters were submitted to a vote, but the nature of these matters is not specified in the provided text.

What financial statements and exhibits are included in this 8-K filing?

The filing lists 'Financial Statements and Exhibits' as an item, but the content of these statements and exhibits is not detailed here.

When was the earliest event reported in this 8-K filing?

The earliest event reported in this 8-K filing was on June 4, 2025.

What is Lipocine Inc.'s principal executive office address?

Lipocine Inc.'s principal executive offices are located at 675 Arapeen Drive, Suite 202, Salt Lake City, Utah 84108.

From the Filing

0001641172-25-013603.txt : 20250604 0001641172-25-013603.hdr.sgml : 20250604 20250604160510 ACCESSION NUMBER: 0001641172-25-013603 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20250604 ITEM INFORMATION: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year ITEM INFORMATION: Submission of Matters to a Vote of Security Holders ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250604 DATE AS OF CHANGE: 20250604 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Lipocine Inc. CENTRAL INDEX KEY: 0001535955 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 990370688 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36357 FILM NUMBER: 251023099 BUSINESS ADDRESS: STREET 1: 675 ARAPEEN DRIVE, SUITE 202 CITY: SALT LAKE CITY STATE: X1 ZIP: 84108 BUSINESS PHONE: 801 994 7383 MAIL ADDRESS: STREET 1: 675 ARAPEEN DRIVE, SUITE 202 CITY: SALT LAKE CITY STATE: X1 ZIP: 84108 FORMER COMPANY: FORMER CONFORMED NAME: MARATHON BAR CORP DATE OF NAME CHANGE: 20111130 8-K 1 form8-k.htm 8-K --12-31 false 0001535955 0001535955 2025-06-04 2025-06-04 iso4217:USD xbrli:shares iso4217:USD xbrli:shares       UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549   FORM 8-K   CURRENT REPORT   Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934   Date of Report (Date of Earliest Event Reported): June 4, 2025       LIPOCINE INC.   (Exact name of registrant as specified in its charter)   Commission File No. 001-36357   Delaware   99-0370688 (State or other jurisdiction of incorporation)   (IRS Employer Identification Number)   675 Arapeen Drive , Suite 202 Salt Lake City , Utah 84108 (Address of principal executive offices) (Zip Code)   Registrant’s telephone number, including area code: (801) 994-7383   Former name or former address, if changed since last report: Not Applicable       Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)     ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)     ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))     ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, par value $0.0001 per share   LPCN   The NASDAQ Stock Market LLC   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR § 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR § 240.12b-2).   Emerging growth company ☐   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐             Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year   As described below, on June 4, 2025, Lipocine Inc. (the “Company”) held its annual general meeting of shareholders, at which a proposal to amend the Company’s Amended and Restated Certificate of Incorporation to reduce the number of authorized shares of the Company’s Common Stock

View on Read The Filing